中国变应性鼻炎和哮喘舌下免疫治疗指南英文版精要解读

Highlights of the Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma(English edition)

近年来,变应原免疫治疗(allergen immunotherapy,AIT)在国内外越来越受到重视,各种临床指南相继出台〔1-4〕,为提高变应性鼻炎(allergic rhinitis,AR)和哮喘的治疗水平提供了理论依据和实践指导。舌下免疫治疗(sublingual immunotherapy,SLIT)是AIT的一种新型治疗方式,自2006年以来在中国临床应用日渐广泛,其疗效和安全性已得到肯定〔5-8〕。为了进一步规范和促进SLIT的临床实践并与国外同行进行学术交流,中华医学会变态反应学分会于2019年12月在Journal of Thoracic Disease发表了中国首部英文版AR和哮喘SLIT指南〔9〕。该指南由来自全国耳鼻咽喉科、儿科、呼吸科、变态反应科等领域28位专家共同撰写完成,主要内容包括AR和哮喘的流行病学、SLIT在AR和哮喘的临床应用及作用机制、SLIT的标准化流程、适应证和禁忌证、治疗过程、总结和展望。

The Chinese guideline on sublingual immunotherapy(SLIT)for allergic rhinitis and asthma(English edition)has been developed by apanel of experts on behalf of the Chinese Society of Allergy,and published in December 2019.The guideline is herein organized to outline the critical items,including the epidemiology of allergic rhinitis and asthma,clinical application and mechanisms of SLIT,standardized procedure,indications and contraindications,therapeutic process,and future perspective,to guide and improve the clinical practice of SLIT.